Pitolisant GR vs Pitolisant (Wakix)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Narcolepsy

Shared mechanism: Histamine H3 receptor (antagonist / inverse agonist) · full Narcolepsy pipeline

Pitolisant GR

Developed by Harmony Biosciences

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Pitolisant (Wakix)

Marketed by Harmony Biosciences and partners

Approved in Narcolepsysmall molecule
Reliable signal

NCT02611687 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial that enrolled 110 children against a planned 108 set by its sample-size calculation. Its primary endpoint, change in narcolepsy symptom score, was met (difference -3.7 points, p=0.007).

Reported efficacy

To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) (met)

Result source: NCT02611687

Results for Narcolepsy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pitolisant GR: no structured comparison results are available for Narcolepsy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pitolisant (Wakix)
To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) NCT02611687 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pitolisant GR's landscape · Pitolisant (Wakix)'s landscape